

Greater Manchester Medicines Management Group

Minutes of the meeting held on
Thursday 12th October 2023, 1-3pm
Via Teams

| Name | Title | Organisation | Representing | May | Jun | Jul | Aug | Sep | Oct |
|-----------------------|--|-------------------------------|------------------------------------|-----|-----|-----|-----|--------------|-----|
| Dr Helen Burgess (HB) | GP MO Prescribing lead | GM ICB - Manchester | GPs | ✓ | ✓ | ✓ | A | ✓ | ✓ |
| Petra Brown (PeB) | Chief Pharmacist | Pennine care NHS FT | GM Mental Health Organisations | ✓ | A | A | ✓ | ✓ SB | ✓ |
| David Hughes (DH) | Locality finance lead | NHS GM Integrated Care | ICB finance | | ✓ | ✓ | ✓ | ✓ | ✓ |
| Kate Rigden (KR) | Director of Finance – Diagnostics and Pharmacy | Northern Care Alliance NHS FT | GM Provider Finance | | ✓ | ✓ | ✓ | A | ✓ |
| Jay Hamilton (TBC) | Programme lead | HiM | Health Innovation Manchester (HiM) | A | ✓ | ✓ | ✓ | ✓ For item 4 | A |
| Dr Ann Harrison (AH) | GP MO Prescribing lead | GM ICB - Trafford | GPs | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Robert Hallworth (RH) | Specialist Cancer Pharmacist | NHSE | NHSE Specialised Commissioning | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Dr Pete Budden | GP Prescribing lead | GM ICB - Salford | GMMMG Clinical Reference Subgroup | ✓ | ✓ | A | ✓ | A | ✓ |
| Aneet Kapoor | Chair of the GM LPN | LPN | Pharmacy profession | ✓ | ✓ | A | A | ✓ | ✓ |
| Vacant seat | | | GM Secondary Care Clinicians | | | | | | |

| | | | | | | | | | |
|---------------------------------|--|------------------------------|--|---|---|---|---|----------------|----------|
| Peter Marks (PM) | LPC Board Member | GM LPC | Community Pharmacy | ✓ | ✓ | ✓ | ✓ | ✓ | A |
| Chris Haigh (CH) | HOMM | GM ICB - Bolton | CCG MO leads and GMMMG Digital subgroup | ✓ | ✓ | ✓ | A | ✓ | ✓ |
| Luvjit Kandula (LK) | Chair – Community Pharmacy Provider Board (CPPB) | GM LPC | Community Pharmacy | ✓ | ✓ | ✓ | ✓ | A | ✓ (part) |
| Lara Shah (LS) | Deputy HOMM | GM ICB - Manchester | GMMMG Population health and inequalities subgroup | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Vacant seat | Interim Deputy Director Strategy – Integrated Care | GM ICB – commissioning (TBC) | ICB Commissioning lead | | | | | | |
| Kenny Li | GM Chief Pharmacist | GM ICB | GMMMG Medicines Value subgroup | ✓ | ✓ | ✓ | ✓ | ✓ for item 1-3 | ✓ (part) |
| Faisal Bokhari or Heather Bury | HOMM | GM ICB – T&G NHS GM ICB | GMMMG Pharmacy workforce subgroup | ✓ | ✓ | A | ✓ | A | A |
| Karen O’Brien (KO’B) | Regional Pharmacist | NHSEI | NHSEI | ✓ | ✓ | A | ✓ | ✓ | A |
| ✓ Paul Buckley (PaB) | Chief Pharmacist | Stockport FT | GM Chief pharmacists | A | A | ✓ | ✓ | ✓ | ✓ |
| Steve Simpson (SS) | Chief Pharmacist | Bolton FT | GM Chief pharmacists | ✓ | A | A | ✓ | ✓ | ✓ |
| Charlotte Skitterall (CS) | Chief Pharmacist | Manchester FT | Chair | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Anna Swift (AS) | Associate Director Medicines Management | GM ICB (Wigan) | GM antimicrobial stewardship group + GM diabetes board | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Claire Vaughan | Director of Quality | GM ICB (Salford) | Vice chair | ✓ | ✓ | ✓ | A | ✓ | A |
| Aleksandra Houghton or Jo Watts | Head of MO/Trust pharmacist | GM ICB/MFT | Co-Chair of GMMMG and GMMMG Medicines Safety subgroup | | | | | ✓ JW | ✓ |
| Dr Sanjay Wahie (SW) | Clinical Director | GM ICB - Wigan | GPs | ✓ | ✓ | A | ✓ | ✓ | ✓ |

| | | | | | | | | | |
|--------------------|-----------------------------|-----------------------------|---|---|---|---|--------------|---|---|
| Dr Peter Elton | SCN representative | Strategic Clinical Network | Strategic Clinical Network | ✓ | ✓ | A | For item 4 ✓ | ✓ | ✓ |
| Vacant seat | | | Provider Board representative | | | | | | |
| Vacant seat | | | Council representative for GM Social Services | | | | | | |
| Vacant seat | | | GM Medical Directors | | | | | | |
| Vacant seat | | | Lay representative | | | | | | |
| Vacant seat | | | GM Public Health | | | | | | |
| Monica Mason (MM) | Head of Prescribing Support | RDTC | Professional secretary | ✓ | ✓ | | ✓ | | |
| Andrew Martin (AM) | MO Pharmacist | GM Joint Commissioning team | GMMM support | ✓ | ✓ | | A | | |
| Dan Newsome (DN) | Principal pharmacist | RDTC | GMMM support | ✓ | A | | ✓ | | |

1. General Business

1.1 Apologies and welcome

As above.

CS temporarily left the meeting during item 4 to take an urgent call. KL and LK were only in attendance towards the end of the meeting.

Declarations of Interest

Nil

2.0 Minutes and actions from the last meeting and update from CEGC and matters arising

Following a minor amendment the minutes were approved for submission to CEGC and onward publication.

GMMM considered a more detailed action and matter arising log, and were updated on progress being made.

GMMM raised to CEGC in Sept the need for additional commissioning of weight management services, it was agreed this information would return to GMMM in 2 months time.

3.0 Medicines decisions for ratification (Sept)

DN reported the recommendations made by the CRG, which included TA902, 905, 907 and the GM commissioning statement for omalizumab for chronic urticaria. All of these recommendations have a financial impact and will need to go to executive for approval via CEGC. It was agreed that a T&F group would be

convened with the SCN to develop A&G for the dapagliflozin TA, this had already been noted as an action for CEG.

The group discussed the need for pathways to be more specific, particularly in terms of use of high cost drugs. DH welcomed this discussion and reiterated the challenging financial position that GM is in.

Other recommendations that could be approved at CEGC include guidance on the long term use of azithromycin in chronic respiratory disease, pathway for the use of high cost drugs in inflammatory bowel disease.

Action: MM to submit GMMM recommendations to the next CEGC meeting. RDTC to publish decisions upon receipt of CEGC approval and where necessary executive approval.

Action: AM/MM to raise to KL the need for a paper to return to GMMM defining the principles of first choice medicines, and the need for specific placing within pathways.

4.0 ADHD medicines shortages: urgent actions to support the GM system

GMMM received at short notice, a number of resources designed to support patients and clinicians through the ADHD medicines national supply problem. GMMM noted that these had been supported by the Clinical reference subgroup 2 days earlier. Jennifer Seal and others were thanked for their hard work and the rapid production of these pieces.

A number of comments had been raised before and during the meeting and the group worked through these and accepted amendments which would be fed back to the authors. The group commented that this was a good example of integrated system working through a challenging situation, it recognised that there was no easy solution but that these resources should be supportive. PB reminded the group of the actions for all sectors from the CAS alert.

However, the GP representation on the group raised their significant concern that primary care would not have capacity to undertake the associated work if this guidance was implemented. They asked that an intermediate solution was instead reached e.g. a phone line which would provide a different route of support for patients.

The Chair accepted that this was a very difficult situation, the pressure of which was being felt nationally. The situation was more challenging as the impact of private providers was difficult to assess, and both secondary and primary care would struggle to manage this situation given current pressures. It was agreed that these comments be taken back to the task and finish group and that the ICB medical director be made aware. A solution is to be returned to GMMM at the earliest opportunity, this should include estimated patient numbers so the impact can be estimated across the system.

Action: MM to communicate to authors and ask that further discussions be undertaken with the T&F group and a solution be returned to GMMM as soon as possible.

5.0 Winter planning activity update

GMMM asked for an update on the winter planning activity and urged the minor ailments scheme be submitted into GMMM as soon as possible, in order that it can be taken through processes as quickly as possible ahead of winter. LK explained that the details of the MAS scheme be returned to GMMM as soon as available.

Action: LK to return the MAS scheme to GMMM asap

6.0 Greater Manchester Wet Age Related Macular Degeneration (AMD) Commissioning Pathway

Due to a lack of time this item was deferred to October meeting

7.0 Regional medicines optimisation opportunities dashboard: GM overview

Due to a lack of time this item was deferred to October meeting

8.0 GMMM medicines value subgroup report

This item was deferred to a future agenda to enable consultation to take place

9.0 GMMMG medicines safety subgroup report

Due to a lack of time this item was deferred to October meeting

10.0 Communication from associated committees

Due to a lack of time this item was deferred to October meeting

AOB

GMMMG expressed their thanks and fond wishes to Dr Helen Burgess who will be stepping down from GMMMG this month. Helen has been a part of GMMMG for over 15 years, she supported the development of the formulary and Chaired GMMMG for many years. Helen will be greatly missed by all of the GMMMG membership who valued her experience, pragmatism and leadership and empathy.

GMMMG await confirmation from the ICB as to the availability of primary care prescribing leads for GMMMG activity going forward.

Date of next meeting: Thursday 9th November 2023, 1-3pm (virtual meeting)